For the latest updates on our ongoing response to COVID-19, please click here.
COMPASS Initiative
Gilead Lift
Gilead HIV Age Positively
TRANScend
HepConnect
What We Fund
Funding Requests
Gilead Foundation
Gilead Public Health Award
Our Business Is Sustainable
Performance
Reporting
U.N. Global Compact
U.N. Sustainable Development Goals
COVID-19
HCV Elimination
U.S. Patient Access
Disaster Product Replacement
Global Access
Authorized Distributors
Governance
Transparency
Policies
Disclosures
Anti-Counterfeiting
Consumer Product Safety
Supplier Information
Anti-Bribery and Anti-Corruption Policy
Political Contributions
Research Scholars Program
Compassionate Use
Investigator-Sponsored Research
Clinical Trials Transparency & Data Sharing Policy
Press Releases
Press FAQS
Gilead Sciences Statement on Recent Events in Washington, D.C.
Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines
Gilead Sciences Statement on the Solidarity Trial
Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations
Year in Review 2019
Cookie Statement
Privacy Shield Covered Entities
Linkedin Guidelines
Twitter Guidelines
Request Medicines Information
Information for Suppliers
Partnership Request
Canada
Mexico
USA
Argentina
Brazil
China
Hong Kong
India
Japan
Korea
Singapore
Taiwan
United Arab Emirates
Saudi Arabia
South Africa
Australia New Zealand
Austria
Belgium Luxembourg
Czech Republic & Slovakia
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Israel
Italy
Netherlands
Norway
Poland & The Baltics
Portugal
Russia
Spain
Sweden
Switzerland
Turkey
United Kingdom
Intersititial body copy
Some content on this site is not intended for people outside the United States.
